Organ or tissue dysfunction due to acute ischemia-reperfusion injury (IRI) is the leading cause of death and disability worldwide. Acute IRI induces cell injury and death in a wide variety of organs and tissues in a large number of different clinical settings. One novel therapeutic non-invasive intervention, capable of conferring multi-organ protection against acute IRI, is 'remote ischemic conditioning' (RIC). This describes an endogenous protective response to acute IRI, which is triggered by the application of one or more brief cycles of non-lethal ischemia and reperfusion to one particular organ or tissue. Originally discovered as a therapeutic strategy for protecting the myocardium against acute IRI, it has been subsequently demonstrated that RIC may confer protection against acute IRI in a number of different non-cardiac organs and tissues including the kidneys, lungs, liver, skin flaps, ovaries, intestine, stomach and pancreas. The discovery that RIC can be induced non-invasively by applying the RIC stimulus to the skeletal tissue of the upper or lower limb, has facilitated its application to a number of clinical settings in which organs and tissues are at high-risk of acute IRI. In this article, we review the experimental studies which have investigated RIC in organs and tissues other than the heart, and we explore the therapeutic potential of RIC in preventing organ and tissue dysfunction induced by acute IRI.
Introduction
Organ or tissue dysfunction arising from acute IRI is the leading cause of death and disability worldwide. Acute IRI induces cell injury and death in a large number of different clinical settings and in a wide variety of organs and tissues including the heart, kidneys, liver, intestine, lungs, brain, skeletal muscle, pancreas, skin, and ovaries. The pathophysiology of IRI and its effects on cellular function and viability are largely similar in these different organs and tissues. It follows then that novel therapeutic strategies for protecting against acute IRI appear to be similarly efficacious in these different organs and tissue. This appears to be the case with the endogenous protective response of remote ischemic conditioning (RIC), in which the application of one or more brief cycles of non-lethal ischemia and reperfusion in one organ or tissue confers protection in remote organs or tissues from a sustained lethal acute episode of IRI 1, 2 . The majority of the experimental studies investigating RIC as a protective therapeutic strategy against acute IRI have revolved around the heart, and this topic is reviewed elsewhere in this special issue. In this article, we focus on the experimental studies which have investigated RIC in organs and tissues other than the heart, and we discuss the therapeutic potential application of RIC for preventing organ and tissue dysfunction in the clinical setting.
Remote ischemic conditioning as an evolving protective strategy
The discovery that the myocardium could be protected against a sustained lethal episode of acute IRI, by subjecting it to one or more brief cycles of non-lethal ischemia and reperfusion, was originally made in 1986 by Murry et al 3 . This endogenous protective response against acute IRI, which was termed 'ischemic preconditioning' (IPC), has been reported to confer cross-species protection in all organs and tissue it has been investigated in 4 . However, the major disadvantage of IPC is the need to intervene before the index ischemic event, thereby limiting its clinical application 5 . This was overcome by the introduction of the concept of ischemic postconditioning in 2003 by Zhao et al. 6 who demonstrated that interrupting myocardial reperfusion with several short-lived episodes of intermittent myocardial ischemia, so as to 'stutter' the reperfusion phase, could reduce myocardial infarct size in the canine heart, providing a therapeutic cardioprotective strategy which could be applied at reperfusion. However, the disadvantage of both IPC and IPost as treatment strategies is that both approaches require the intervention to be applied to the organ or tissue directly, which in some cases may not be feasible or practical 7 . This obstacle was overcome by the discovery of 'remote ischemic preconditioning' (RIPC) in 1993 1 , a therapeutic strategy for protecting organs and tissues against acute IRI by applying the protective stimulus away from the target organ or tissue.
The concept of protecting an organ or tissue against acute IRI at a distance was first conceived in a seminal experimental study in 1993 by Przyklenk et al 1 .
These authors demonstrated in the canine heart, that applying four 5-minute episodes of left circumflex branch occlusion and 5-minute reflow, reduced myocardial infarct (MI) size induced by 1 hour of sustained left anterior descending (LAD) coronary artery occlusion and 4.5 hours of reflow 1 . The concept that protection against acute IRI could be transferred from one coronary artery territory to another was then extended to protecting the heart at a distance by applying the preconditioning stimulus to an organ 'remote' from the heart by McClanahan et al in 1993 8 . These authors demonstrated that subjecting the kidney to brief cycles of nonlethal ischemia and reperfusion (IR) could limit subsequent MI size in the rat heart 8 .
Later in 1997, Birnbaum et al 9 made the important discovery that RIPC could be induced by subjecting the skeletal muscle of the hind-limb to brief cycles of nonlethal ischemia and reperfusion. These authors observed, that briefly restricting blood flow to the skeletal muscle of the lower limb and pacing the gastrocnemius leg muscle prior to an acute coronary artery occlusion, reduced MI size in the rabbit heart 9 . A non-invasive method for applying the RIPC stimulus to the hind-limb using external compression with a tourniquet was then introduced by Oxman et al 10 , a finding which has greatly facilitated the translation of RIPC as an experimental phenomenon into a potential non-invasive therapeutic strategy in the clinical setting.
In this regard, the first clinical study to investigate RIPC in patients was by Gunaydin et al in 2000 11 , who inflated and deflated a standard blood pressure cuff placed on the upper arm to non-invasively induce the RIC stimulus in patients prior to coronary artery bypass graft (CABG) surgery. However, the study was underpowered to detect any meaningful differences in the effect of RIC on peri- Crucially, experimental studies have demonstrated that the RIC stimulus does not have to be applied prior to the index ischemic event to be effective (as in 'remote ischemic preconditioning' or RIPC), but can be applied after the onset of index ischemia (termed 'remote ischemic perconditioning' or RIPerC) 13 , and even at the time of reperfusion (termed 'remote ischemic postconditioning' or RIPost) 14, 15 . The finding that the RIC stimulus can be effective when delivered at different time-points during the index episode of acute IRI has also increased it applicability to a number of different clinical settings. The term, remote ischemic conditioning (RIC), has been introduced to refer to these different protective phenomena and will be used from this point forward.
The recognition that a single RIC stimulus could confer multi-organ and tissue protection against acute IRI has led to it being extensively investigated not only in the field of myocardial protection but also in a wide variety of other non-cardiac organs or tissues such as the kidneys, lungs, liver, brain, stomach, intestine, pancreas and ovaries, in which acute IRI also causes significant morbidity and mortality. The mechanisms underlying RIC protection against acute IRI remain uncertain and are discussed elsewhere in this special issue. Throughout this review article, the reader will note the widely varying RIC protocols that have been used in the experimental studies. Unfortunately, insufficient work has been undertaken to ascertain the optimal RIC protocol in terms of its efficacy. If RIC is to succeed as a clinical applicable intervention both these issues will need to be addressed by further experimental study.
Remote ischemic conditioning and the kidney
Acute kidney injury (AKI) due to acute IRI is a frequent cause of morbidity and mortality following a number of medical conditions and operative procedures. AKI is a condition frequently encountered in the period that follows major surgery and which is associated with significant morbidity and mortality. In the setting of cardiac surgery it can affect up to 30% of patients resulting in renal dialysis, in 1-2% of cases 16 , the repercussions of which include an eight-fold increase in death rate 17 . AKI is also a common complication of major vascular surgery involving the abdominal aorta, and can occur in up to 10% of these patients 18 , where it is an independent predictor of death 19 . Aortic cross-clamping and de-clamping during the surgical procedure subjects the kidneys to acute IRI 20 .
Different mechanisms have been hypothesized to explain the etiology underlying renal injury following cardiac surgery and these include hemodynamic effects related to cardiopulmonary bypass (CBP), metabolic factors, neuro-hormonal stimulation, the systemic inflammatory response to CBP, exogenous and endogenous toxins, and the production of micro-emboli and oxidative stress 16 .
Importantly, despite a number of different preventative strategies being investigated to preserve renal function following cardiac surgery, the results have been disappointing 16 . Therefore, novel renoprotective strategies are required to protect the kidneys against acute IRI in order to reduce the incidence of AKI and improve clinical outcomes in these patients.
The experimental data for RIC as a renoprotective strategy
A number of experimental studies have investigated the effect of IPC as a therapeutic strategy for limiting acute renal IRI (reviewed in 21 ) . However, only a few experimental studies have explored the effect of RIC in preventing acute IRI in the kidney (see Table 1a ). Beneficial effects have been reported using a diverse variety of RIC protocols applied to different organs or tissues including the liver, small intestine, subphrenic aorta and the hindlimb. The study by Wever et al 22 , which used limb RIC, attempted to characterize the RIC stimulus, and as expected they were able to show that the protective effect was augmented when the RIC stimulus was applied to both hindlimbs instead of one. Importantly, Kadkhodaee et al 23 demonstrated that the RIC limb stimulus was effective even when applied after the onset of index renal ischemia (RIPerC) and even at the onset of renal reperfusion (RIPost), thereby broadening the clinical application of RIC as a therapeutic renoprotective strategy. Finally, the concept of combining renoprotective stimuli has been recently investigated by Wever et al 24 , who demonstrated the synergistic effects on preserving renal function using RIPost and a local IPost protocol in combination.
The clinical data for RIC as a renoprotective strategy
Several clinical studies have investigated the effect of RIC using repeated cycles of upper arm or leg ischemia and reperfusion on preventing renal dysfunction and the development of acute kidney injury (AKI) following a number of medical and surgical procedures including percutaneous coronary intervention (PCI), CABG surgery, renal transplantation, abdominal aortic aneurysm surgery, and other major vascular surgery (see Table 1b ). However, not all the clinical studies have reported a beneficial effect of RIC as a renoprotective strategy with some studies being neutral.
The reasons for the mixed results are multi-factorial and have been discussed in relation to myocardial protection in several recently published articles [25] [26] [27] [28] 
Remote ischemic conditioning and the lungs
Acute lung injury is a major cause of morbidity and mortality in a number of clinical settings including cardiac surgery, orthopedic surgery, lung resection surgery and lung transplantation. In the setting of CABG surgery, the main contributory mechanisms underlying pulmonary dysfunction include cardiopulmonary bypass (CBP)-induced systemic cytokine-mediated inflammatory response and acute lung IRI 31 , resulting in poor alveolar oxygenation and increased pulmonary vascular resistance leading to prolonged requirement for artificial ventilation 32, 33 .
The experimental data for RIC as a lung protective strategy
One of the first experimental studies to investigate the effect of RIC on acute lung injury was by Peralta et al in 2002 34 who demonstrated in the rat that applying a RIC stimulus to the liver reduced systemic inflammation and attenuated neutrophil accumulation in the lung and other organs following a sustained liver IRI. Since this study a number of studies have examined the effect of RIC in preventing acute lung IRI in a wide variety of experimental models (see Table 2a ).
The clinical data for RIC as a lung protective strategy
A number of clinical studies have investigated the effect of RIC on pulmonary function following mainly cardiac surgery, although there has been one study in orthopaedic surgery (see Table 2b ). The first clinical study to demonstrate a beneficial effect of RIC on pulmonary function was by Li et al in 2001 35 who demonstrated that RIC of the heart could preserve pulmonary function following adult cardiac valve surgery. However, in the majority of the clinical studies, the main objective has been to evaluate the effect of RIC on cardioprotection, and the endpoints of pulmonary function, were usually secondary objectives of the study. In this regard, RIC appears to have some beneficial effects on preserving pulmonary function in pediatric cardiac surgery and following orthopedic surgery. However, it appears that RIC has little effect on ventilation times following adult cardiac surgery, which may be expected given that there are a large number of factors other than acute IRI which contribute to the length of ventilation post-cardiac surgery. It will be interesting to examine the effect of RIC in clinical settings in which acute lung IRI is the predominant insult such as in cases of lung resection surgery and lung transplantation. In this regard, on-going clinical studies are currently evaluating the effects of RIC on pulmonary function in the setting of pulmonary lobectomy (ClinicalTrials.gov identifier: NCT01307085) and elective abdominal aortic aneurysm repair (ClinicalTrials.gov NCT01344239).
Remote ischemic conditioning and the liver
During major liver surgery, intra-or post-operative blood loss with subsequent requirement of blood transfusion is associated with worse clinical outcomes 36, 37 .
Vascular clamping of the hepatic territory can prevent or minimise this risk although it is itself associated with acute liver IRI due to clamping and subsequent unclamping of the portal triad 38, 39 . The mechanism underlying acute hepatic IRI is likely to be related to the significant amount of oxygen-derived free radicals accumulating in the liver during reperfusion, particularly in those cases of resected or cirrhotic liver when acute IRI is poorly tolerated due to impaired compensatory mechanisms, leading to post-operative hepatic and multi-organ failure 38 .
The experimental data for RIC as a liver protective strategy
The first experimental study to demonstrate benefit with limb RIC was by Lai et al 40 who found that four-10 min cycles of hind-limb ischemia and reperfusion reduced acute liver IRI as evidenced by an attenuated increase in the serum liver enzyme ALT (alanine aminotransferase). In this initial study, RIC protection was associated with the activation of hemoxygenase-1 (HO-1), a known mediator of direct IPC 40 .
Since this publication, a number of experimental studies, using a wide variety of different RIC protocols, have confirmed the protective effects of limb RIC against acute liver IRI in the rat, rabbit and mouse (see Table 3 for summary). The mechanism underlying the protective effect is unclear, although potential mediators include components of the nitric oxide pathway (sGC, cGMP, eNOS) [41] [42] [43] and the Toll-4 receptor signalling pathway. An exciting recent study has suggested that limb RIC may not only be able to protect against acute liver IRI, but it may actually promote liver regeneration in small liver grafts following liver transplantation 44 . Wang et al 44 demonstrated that a standard limb RIC protocol increased the proliferation index in the liver graft, findings which were associated with enhanced expression of interleukin-6 mRNA and suppressed expression of TNF-α.
The clinical data for RIC as a liver protective strategy
Two randomised controlled clinical trials are currently investigating the therapeutic potential of RIC in the clinical setting of acute hepatic IRI. In the first study, based in the UK, Davidson and colleagues are exploring whether RIC (three-10 min cycles thigh cuff inflation/deflation) can reduce acute liver IRI (serum hepatic and tissue biomarkers) in patients undergoing liver surgery and orthotopic liver transplantation (ClinicalTrials.gov identifier: NCT00796588). In the second study, based in the USA, Koneru and colleagues will evaluate short and long-term clinical outcomes in patients receiving liver, kidney or pancreas transplantation from deceased organ donors previously randomised to either RIC (two-10 min cycles of inflation/deflation of a blood pressure cuff applied sequentially on each leg) (Remote Ischemic Preconditioning In Abdominal Organ Transplantation [RIPCOT]; ClinicalTrials.gov identifier: NCT00975702). The results from these two studies should inform us of the therapeutic potential of RIC in preventing acute liver IRI in patients undergoing major abdominal surgery or organ transplantation.
Remote ischemic conditioning and the brain
There are a number of clinical settings in which the brain is subjected to acute IRI including the setting of stroke and during carotid endarterectomy (CEA). Stroke is currently the second most common cause of death worldwide, after coronary artery disease 45 , and is responsible for nearly 10% of all deaths around the world 46 . In 2002, stroke-related disability was estimated as the fifth most common cause of reduced disability-adjusted life-years (DALYs-the sum of life-years lost as a result of premature death and years lived with disability adjusted for severity) in low-income and middle-income countries 46 . CEA has been recognised as an effective strategy for stroke prevention in both symptomatic and asymptomatic patients 47-50 . However CEA itself carries important peri-operative risks, with an estimated mortality rate of 1%, perioperative stroke rate of 3-5%, and a major cardiac complication rate (myocardial infarction, unstable angina, pulmonary edema, or ventricular tachycardia) of 4% 51, 52 .
The experimental data for RIC as a neuroprotective strategy
As a potentially novel neuroprotective intervention, RIC has been extensively studied Table 4 ). The first experimental study to evaluate RIC as a neuroprotective strategy was by Dave et al 53 who found that RIC (either a single episode of 15 or 30 minutes of hindlimb ischemia and reperfusion) could protect the rat brain against acute IRI induced by asphyxial cardiac arrest. Crucially, the RIC stimulus has been shown to be effective at a number of different time-points in relation to the cerebral IRI broadening its scope for application in the clinical setting. The RIC stimulus can be applied one or two days prior to the index cerebral ischemia (delayed RIPC), immediately prior to the index cerebral ischemia (classical RIPC), after the onset of the index cerebral ischemia (RIPerC), at the onset of cerebral reperfusion (RIPost) 54 and even when delayed up to 3 hours into the reperfusion phase (delayed RIPost) 54 ( Table 4 ). The ability to protect the brain against acute IRI with the RIC delivered 3 hours into reperfusion would have important clinical implications. Whether delaying the RIC stimulus into reperfusion is effective in protecting other organs or tissue against acute IRI is unknown, although this approach does appear to contradict the current paradigm that, for a protective intervention to be effective it needs to be applied at the onset of reperfusion. Interestingly, a recent experimental study has demonstrated that local IPost applied direct to the heart could limit myocardial infarct size in a murine model of acute IRI, even when delivered up to 30 min into reperfusion 55 . demonstrate that RIC (two-5 min cycles of myocardial or hepatic ischemia and reperfusion) could protect the stomach against acute IRI. RIC gastric protection was found to be abrogated in capsaicin-denervated or vagotomised rats.
The clinical data for RIC as a neuroprotective strategy
Combined pancreas-kidney transplantation has recently been successfully implemented for patients with type 1 diabetes and end-stage renal failure 72 . This operation can be complicated by graft pancreatitis, a contributing factor of which is acute IRI, resulting in graft loss 73 . Oehmann et al 74 were the first to demonstrate that RIC (15 minutes of infrarenal aortic ischemia and reperfusion) could protect the pancreas against acute IRI as evidenced by improved circulation, reduced inflammatory tissue response and histology damage. RIC-mediated protection against acute pancreatic IRI has been confirmed by a subsequent study 75 , although not all studies have been positive 76 .
In terms of clinical application, a large randomised controlled clinical trial is underway investigating the effect of RIC on clinical outcomes following combined liver, kidney or pancreas transplantation (ClinicalTrials.gov identifier: NCT00975702).
Remote ischemic conditioning and skin flaps
In the setting of trauma, plastic and reconstructive surgery, soft tissue coverage is usually performed with the use of local or free skin flaps, a surgical procedure which is associated with significant morbidity due to the risk of necrosis of the implanted flap in 1-5% of cases 77, 78 . This is likely to be caused by prolonged post-operative flap ischemia when the flap is exposed to during the surgery. Küntscher et al [79] [80] [81] were the first to demonstrate that hindlimb RIC (10 min clamping of femoral artery) could protect muscle flaps against IRI. Whether, this RIC is beneficial in the clinical setting of plastic surgery is currently being tested in patients undergoing skin flap transplantation to the anterolateral thigh (ClinicalTrials.gov identifier: NCT01235286).
It is interesting to note that upper arm RIC has been recently demonstrated to improve cutaneous tissue oxygen saturation, arterial capillary blood flow and postcapillary venous filling pressure in the skin of the contralateral thigh in human volunteers 82 .
Remote ischemic conditioning and the ovaries
Ovarian auto-transplantation is an increasingly used procedure for maintaining fertility in women receiving cytotoxic treatment for malignant disease or immunosuppressive disorders, which ultimately cause early ovary failure 83, 84 . This has been observed in up to 34% of women receiving chemotherapy and 92% of patients having radio-or chemo-therapy for bone marrow transplantation 85 . Acute IRI of the graft ovary is one of the major factors responsible for preventing graft revascularization and success of ovarian transplantation 86 . It has been demonstrated that hindlimb RIC in the rat improves ovarian viability, vascularization and vasodilatation, findings which were associated with increased serum oestradiol levels, improved graft morphology and follicular maturity 87, 88 . This novel application of RIC in improving the success of ovarian transplantation remains to be explored in the clinical setting.
Conclusions
Although remote ischemic conditioning (RIC) was first discovered as a non-invasive therapeutic strategy for protecting the heart from a distance, its potential for conferring widespread protection against acute IRI in a number of different noncardiac organs and tissues has now been realized. Experimental studies have demonstrated beneficial effects of RIC against acute IRI in a wide variety of organs and tissues including kidney, liver, brain, skin flaps, ovaries, intestine, stomach and the pancreas. Further study is now needed to characterize the optimal RIC protocol in terms of efficacy and to elucidate the mechanisms underlying its protective effect.
The ability to induce RIC by simply applying the protective stimulus to the arm or leg 
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Figure legend
This figure demonstrates the non-cardiac organs and tissue in which remote ischemic conditioning (RIC, inflations and deflations of a blood pressure cuff placed on the upper arm or thigh to induce cycles of non-lethal ischemia and reperfusion) may offer protection against acute ischemia-reperfusion injury (IRI). In each organ and tissue, there are number of clinical settings in which RIC has been or is currently being investigated as a therapeutic strategy or in which the potential for clinical application exists. No effect on PaO2/FiO2 or incidence of acute lung injury (was defined as PaO2/FiO2 <300 mmHg, the detection of bilateral pulmonary infiltrates on frontal chest radiography and no clinical evidence of further elevation in the left atrial pressure.
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No effect on ventilation time CABG-coronary artery bypass graft, OPCABG-off-pump coronary artery bypass graft, RIC-remote ischemic conditioning, PaO2/FiO2-oxygen tension/Fraction of inspired oxygen ratio, Cs-static compliance, mmHg-millimetres of mercury 
